The prognostic role of ventilatory inefficiency and exercise capacity in idiopathic pulmonary fibrosis

Respiratory Care

Volumn 61, Issue 8, 2016, Pages 1100-1109

  Vainshelboim, Baruch ^a,b   Oliveira, Jose ^b   Fox, Benjamin Daniel ^a,c   Kramer, Mordechai Reuven ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PORTO   (Portugal)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiopulmonary exercise test ing; Exercise intolerance; Prognostic predictors; Survival; Ventilatory response

Indexed keywords

ADULT; AGED; ANAEROBIC THRESHOLD; ARTICLE; ASSISTED VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEVICE FAILURE; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; EXERCISE TEST; FEMALE; FIBROSING ALVEOLITIS; HEART RATE; HIGH RISK PATIENT; HUMAN; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MORTALITY RATE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; ROD WALKING TEST; SURVIVAL RATE; TIDAL VOLUME; VERY ELDERLY; COMPLICATION; EVALUATION STUDY; EXERCISE TOLERANCE; LUNG VENTILATION; LUNG VOLUME; MORTALITY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RISK ASSESSMENT; STANDARD; STANDARDS;

AGED; AGED, 80 AND OVER; ANAEROBIC THRESHOLD; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY VENTILATION; REFERENCE STANDARDS; REGRESSION ANALYSIS; RISK ASSESSMENT; ROC CURVE; SURVIVAL RATE;

EID: 84982272581     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.04471     Document Type: Article

References (42)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824.
2. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183(4):431-440.
4. Fernández Pérez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137(1):129-137.
5. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012;40(1):101-109.
6. Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 2014;14:139.
7. King TE, Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164(7):1171-1181.
8. Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration 2009;77(1):3-17.
9. ERS Task Force, Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007;29(1):185-209.
10. Arena R, Sietsema KE. Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. Circulation 2011;123(6):668-680.
11. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician’s Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010;122(2):191-225.
12. American Thoracic Society, American College of Chest Physicians. Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167(2):211-277.
13. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. EACPR/AHA scientific statement: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2012;126(18):2261-2274.
14. Wallaert B, Guetta A, Wemeau-Stervinou L, Tercé G, Valette M, Nevière R, et al. [Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis]. Rev Mal Respir 2011;28(3):290-296.
15. Triantafillidou C, Manali E, Lyberopoulos P, Kolilekas L, Kagouri-dis K, Gyftopoulos S, et al. The role of cardiopulmonary exercise test in IPF prognosis. Pulm Med 2013. doi: 10.1155/2013/514817.
16. Holland AE. Exercise limitation in interstitial lung disease: mechanisms, significance and therapeutic options. Chron Respir Dis 2010; 7(2):101-111.
17. Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med 2004;25(3):435-453, v.
18. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Part 1):646-664.
19. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179(5):402-407.
20. Miki K, Maekura R, Hiraga T, Okuda Y, Okamoto T, Hirotani A, Ogura T. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med 2003;97(5): 482-490.
21. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, Kramer MR. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 2014;88(5):378-388.
22. Florey CD. Sample size for beginners. BMJ 1993;306(6886):1181- 1184.
23. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;63(6):549-554.
24. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93(3):580-586.
25. Papiris SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, Roussos C. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005;99(6):755-761.
26. Schiller NB. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography. Circulation 1991;84(3 Suppl):I280–I287.
27. Schiller NB. Pulmonary artery pressure estimation by Doppler and two-dimensional echocardiography. Cardiol Clin 1990;8(2):277-287.
28. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-1263.
29. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26(4):720-735.
30. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J 2005;26(1):153-161.
31. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26(3):511-522.
32. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Ye-rnault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
33. Pescatello LS, American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. Philadelphia: Wolters Klu-wer/Lippincott Williams & Wilkins Health; 2014.
34. Wasserman K. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. Philadelphia: Lip-pincott Williams & Wilkins; 2005.
35. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166(1):111-117.
36. Jenkins S, Hill K, Cecins NM. State of the art: how to set up a pulmonary rehabilitation program. Respirology 2010;15(8):1157-1173.
37. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J 2012;24(3):69-71.
38. Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung 2015;193(3): 345-354.
39. Gläser S, Obst A, Koch B, Henkel B, Grieger A, Felix SB, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis: the predictive value of exercise capacity and gas exchange efficiency. PLoS One 2013;8(6):e65643.
40. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009;103(1):117-123.
41. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014;43(5):1421-1429.
42. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011;97(8):612-622.